Junko Takeshita1, Shuwei Wang2, Daniel B Shin1, Nehal N Mehta3, Stephen E Kimmel4, David J Margolis1, Andrea B Troxel5, Joel M Gelfand1. 1. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia2Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia. 2. Division of Internal Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania. 3. Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland. 4. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia5Division of Cardiology, University of Pennsylvania Perelman School of Medicine, Philadelphia. 5. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Abstract
IMPORTANCE: Hypertension is prevalent among patients with psoriasis. The effect of psoriasis and its severity on hypertension control is unknown. OBJECTIVE: To determine the association between uncontrolled blood pressure and psoriasis, both overall and according to objectively measured psoriasis severity, among patients with diagnosed hypertension. DESIGN, SETTING, AND PARTICIPANTS: Population-based cross-sectional study nested in a prospective cohort drawn from The Health Improvement Network (THIN), an electronic medical records database broadly representative of the general population in the United Kingdom. The study population included a random sample of patients with psoriasis (n = 1322) between the ages of 25 and 64 years in THIN who were included in the Incident Health Outcomes and Psoriasis Events prospective cohort and their age- and practice-matched controls without psoriasis (n = 11,977). All included patients had a diagnosis of hypertension; their psoriasis diagnosis was confirmed and disease severity was classified by their general practitioners. MAIN OUTCOMES AND MEASURES: Uncontrolled hypertension was defined as a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher based on the blood pressure recorded closest in time to the assessment of psoriasis severity. RESULTS: There was a significant positive dose-response relationship between uncontrolled hypertension and psoriasis severity as objectively determined by the affected body surface area in both unadjusted and adjusted analyses that controlled for age, sex, body mass index, smoking and alcohol use status, presence of comorbid conditions, and current use of antihypertensive medications and nonsteroidal anti-inflammatory drugs (adjusted odds ratio [aOR], 0.97; 95% CI, 0.82-1.14 for mild psoriasis; aOR, 1.20; 95% CI, 0.99-1.45 for moderate psoriasis; and aOR, 1.48; 95% CI, 1.08-2.04 for severe psoriasis; P = .01 for trend). The likelihood of uncontrolled hypertension among psoriasis overall was also increased, although not statistically significantly so (aOR, 1.10; 95% CI, 0.98-1.24). CONCLUSIONS AND RELEVANCE: Among patients with hypertension, psoriasis was associated with a greater likelihood of uncontrolled hypertension in a dose-dependent manner, with the greatest likelihood observed among those with moderate to severe psoriasis defined by 3% or more of the body surface area affected. Our data suggest a need for more effective blood pressure management, particularly among patients with more severe psoriasis.
IMPORTANCE: Hypertension is prevalent among patients with psoriasis. The effect of psoriasis and its severity on hypertension control is unknown. OBJECTIVE: To determine the association between uncontrolled blood pressure and psoriasis, both overall and according to objectively measured psoriasis severity, among patients with diagnosed hypertension. DESIGN, SETTING, AND PARTICIPANTS: Population-based cross-sectional study nested in a prospective cohort drawn from The Health Improvement Network (THIN), an electronic medical records database broadly representative of the general population in the United Kingdom. The study population included a random sample of patients with psoriasis (n = 1322) between the ages of 25 and 64 years in THIN who were included in the Incident Health Outcomes and Psoriasis Events prospective cohort and their age- and practice-matched controls without psoriasis (n = 11,977). All included patients had a diagnosis of hypertension; their psoriasis diagnosis was confirmed and disease severity was classified by their general practitioners. MAIN OUTCOMES AND MEASURES: Uncontrolled hypertension was defined as a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher based on the blood pressure recorded closest in time to the assessment of psoriasis severity. RESULTS: There was a significant positive dose-response relationship between uncontrolled hypertension and psoriasis severity as objectively determined by the affected body surface area in both unadjusted and adjusted analyses that controlled for age, sex, body mass index, smoking and alcohol use status, presence of comorbid conditions, and current use of antihypertensive medications and nonsteroidal anti-inflammatory drugs (adjusted odds ratio [aOR], 0.97; 95% CI, 0.82-1.14 for mild psoriasis; aOR, 1.20; 95% CI, 0.99-1.45 for moderate psoriasis; and aOR, 1.48; 95% CI, 1.08-2.04 for severe psoriasis; P = .01 for trend). The likelihood of uncontrolled hypertension among psoriasis overall was also increased, although not statistically significantly so (aOR, 1.10; 95% CI, 0.98-1.24). CONCLUSIONS AND RELEVANCE: Among patients with hypertension, psoriasis was associated with a greater likelihood of uncontrolled hypertension in a dose-dependent manner, with the greatest likelihood observed among those with moderate to severe psoriasis defined by 3% or more of the body surface area affected. Our data suggest a need for more effective blood pressure management, particularly among patients with more severe psoriasis.
Authors: Lars Lund; Jacob Jacobsen; Mette Nørgaard; Joseph K McLaughlin; William J Blot; Michael Borre; Henrik T Sørensen Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: William B White; Christine R West; Jeffrey S Borer; Philip B Gorelick; Lisa Lavange; Sharon X Pan; Ethan Weiner; Kenneth M Verburg Journal: Am J Cardiol Date: 2006-11-10 Impact factor: 2.778
Authors: Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel Journal: J Invest Dermatol Date: 2009-05-21 Impact factor: 8.551
Authors: George Martin; Bruce E Strober; Craig L Leonardi; Joel M Gelfand; Andrew Blauvelt; Arthur Kavanaugh; Linda Stein Gold; Brian Berman; Ted Rosen; Eggert Stockfleth Journal: J Clin Aesthet Dermatol Date: 2016-09-01
Authors: Young S Oh; Lawrence J Appel; Zorina S Galis; David A Hafler; Jiang He; Amanda L Hernandez; Bina Joe; S Ananth Karumanchi; Christine Maric-Bilkan; David Mattson; Nehal N Mehta; Gwendolyn Randolph; Michael Ryan; Kathryn Sandberg; Jens Titze; Eser Tolunay; Glenn M Toney; David G Harrison Journal: Hypertension Date: 2016-06-20 Impact factor: 10.190
Authors: Marilyn T Wan; Daniel B Shin; Rebecca A Hubbard; Megan H Noe; Nehal N Mehta; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2017-11-08 Impact factor: 11.527
Authors: Li-Hao Huang; Bernd H Zinselmeyer; Chih-Hao Chang; Brian T Saunders; Andrew Elvington; Osamu Baba; Thomas J Broekelmann; Lina Qi; Joseph S Rueve; Melody A Swartz; Brian S Kim; Robert P Mecham; Helge Wiig; Michael J Thomas; Mary G Sorci-Thomas; Gwendalyn J Randolph Journal: Cell Metab Date: 2018-11-08 Impact factor: 27.287
Authors: Kashif Jafri; Christie M Bartels; Daniel Shin; Joel M Gelfand; Alexis Ogdie Journal: Arthritis Care Res (Hoboken) Date: 2016-11-28 Impact factor: 4.794
Authors: Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2017-03 Impact factor: 11.527
Authors: Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2017-03 Impact factor: 11.527